Back to Newsroom
Back to Newsroom

CLASS ACTION UPDATE for BLUE, EBIX and VLDR: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Thursday, 04 March 2021 10:45 AM

Levi & Korsinsky, LLP

Topic:
Lawsuits

NEW YORK, NY / ACCESSWIRE / March 4, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.

BLUE Shareholders Click Here: https://www.zlk.com/pslra-1/bluebird-bio-inc-loss-form?prid=13314&wire=1
EBIX Shareholders Click Here: https://www.zlk.com/pslra-1/ebix-inc-loss-submission-form?prid=13314&wire=1
VLDR Shareholders Click Here: https://www.zlk.com/pslra-1/velodyne-lidar-inc-loss-submission-form?prid=13314&wire=1

* ADDITIONAL INFORMATION BELOW *

Levi & Korsinsky, LLP, Thursday, March 4, 2021, Press release picture

bluebird bio, Inc. (NASDAQ:BLUE)

BLUE Lawsuit on behalf of: investors who purchased May 11, 2020 - November 4, 2020
Lead Plaintiff Deadline : April 13, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/bluebird-bio-inc-loss-form?prid=13314&wire=1

According to the filed complaint, during the class period, bluebird bio, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) data supporting bluebird's BLA submission for LentiGlobin for SCD was insufficient to demonstrate drug product comparability; (ii) Defendants downplayed the foreseeable impact of disruptions related to the COVID-19 pandemic on the Company's BLA submission schedule for LentiGlobin for SCD, particularly with respect to manufacturing; (iii) as a result of all the foregoing, it was foreseeable that the Company would not submit the BLA for LentiGlobin for SCD in the second half of 2021; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

Ebix, Inc. (NASDAQ:EBIX)

EBIX Lawsuit on behalf of: investors who purchased November 9, 2020 - February 19, 2021
Lead Plaintiff Deadline : April 23, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/ebix-inc-loss-submission-form?prid=13314&wire=1

According to the filed complaint, during the class period, Ebix, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) that there was insufficient audit evidence to determine the business purpose of certain significant unusual transactions in Ebix's gift card business in India during the fourth quarter of 2020; (2) that there was a material weakness in Company's internal controls over the gift or prepaid revenue transaction cycle; and (3) that the Company's independent auditor was reasonably likely to resign over disagreements with Ebix regarding $30 million that had been transferred into a commingled trust account of Ebix's outside legal counsel; and (4) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Velodyne Lidar, Inc. (NASDAQ:VLDR)

VLDR Lawsuit on behalf of: investors who purchased November 9, 2020 - February 19, 2021
Lead Plaintiff Deadline : May 3, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/velodyne-lidar-inc-loss-submission-form?prid=13314&wire=1

According to the filed complaint, during the class period, Velodyne Lidar, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) certain of Velodyne's directors had failed to operate with respect, honesty, integrity, and candor in their dealings with the Company's officers and directors; (2) the Company was investigating the foregoing matters; and (3) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

Topic:
Lawsuits
Back to newsroom
Back to Newsroom
Share by: